This delivery platform allows high-concentration biologics—like mAbs, RNA drugs, and vaccines—to be administered via subcutaneous injection using hyaluronidase, novel excipients, and nanocarriers. It enables larger volumes (up to ≥5 mL) to be injected with reduced discomfort, eliminating the need for IV infusion. Applications span oncology, autoimmune diseases, and hormone therapies, with advantages in self-administration, outpatient care, and stable formulations for remote or emergency use. Backed by TRL 9 and widely adopted, this approach is a breakthrough in drug delivery innovation, improving patient experience and scalability of biologics.
